TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7654164
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trust and explanation
Study: 7195414
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (1 g four times a day) for 14 days
Study: 7195414
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg four times a day) for 14 days
Study: 7195414
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg four times a day) for 3 days
Study: 30782673
Drug: Buried intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buried intradermal suture (BIS)
Study: 28592063
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 2.5%
Study: 28592063
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.0%
Study: 11465619
Drug: Propofol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target concentration, 1.5 microg/ml)
Study: 11465619
Drug: Alfentanil (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (12.5 microg/kg intravenous followed by 25 microg.kg(‐1).h(‐1))
Study: 7604347
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection alone
Study: 7604347
Drug: Laminectomy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminectomy for failed intradiscal injection
Study: 2196144
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg) administered twice daily for 4 weeks
Study: 517713
Drug: Glycopyrrolate 0.6
Normalized name: glycopyrrolate 0.6 MG in 3 mL Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.6 mg and Neostigmine 2.5 mg i.v.
Study: 517713
Drug: Glycopyrrolate 0.6
Normalized name: glycopyrrolate 0.6 MG in 3 mL Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.6 mg and Neostigmine 5 mg i.v.
Study: 30325613
Drug: Artificial urethral
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial urethral sphincter (AUS) implant 'BR - SL - AS - 904'
Study: 20233182
Drug: R‐(‐)‐MA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐(‐)‐MA 0.25 mg kg(‐1)
Study: 20233182
Drug: S‐(+)‐MA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐(+)‐MA 0.25 mg kg(‐1)
Study: 14683659
Drug: Abacavir-lamivudine-tenofovir combination
Normalized name: abacavir / lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir-lamivudine-tenofovir combination treatment
Study: 1497770
Drug: Single-dose cefuroxim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefuroxim (Zinacef)
Study: 6836645
Drug: Nimodipine infusion
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine infusion (1 microgram kg-1 min-1)
Study: 2859782
Drug: Once-daily treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily treatment (n = 97)
Study: 2859782
Drug: Twice-daily treatment
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily treatment (n = 47)
Study: 2859782
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (n = 48)
Study: 30051198
Drug: Pasireotide-LAR (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide-LAR (40 mg/4 weeks)
Study: 27966503
Drug: Herbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulation toothpaste
Study: 24730399
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine hydrochloride 1%
Study: 15778231
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus acupuncture
Study: 12564745
Drug: Fast-melting tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-melting tablet
Study: 12564745
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin preparation
Study: 16533451
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin 10 IU
Study: 1346558
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg 3 times daily)
Study: 30577902
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment in jail-based program
Study: 30577902
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment in community programs
Study: 26581034
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (control phase)
Study: 6203024
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (chemotherapy + multiple fractionated radiation therapy)
Study: 6203024
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily fractionated radiation therapy
Study: 6203024
Drug: Single-modality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-modality therapy (chemotherapy alone or radiation therapy alone)
Study: 30659041
Drug: TN‐TC11LM (THC:CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: TN‐TC11LM (THC:CBD in 1:1 ratio) capsules daily for 12 weeks
Study: 30659041
Drug: TN‐TC19LM (THC:CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: TN‐TC19LM (THC:CBD in 1:9 ratio) capsules daily for 12 weeks
Study: 30659041
Drug: TN‐TC11LM and
Approvals — FDA: no, EMA: no, PMDA: no
Description: TN‐TC11LM and TN‐TC19LM capsules
Study: 29437074
Drug: Dexmedetomidine (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (self-administered sedation)
Study: 22078345
Drug: L-ornithine-L-aspartate (LOLA)
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (LOLA)
Study: 18201764
Drug: Perifosine 100
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine 100 mg daily or 900 mg weekly in combination with imatinib
Study: 18201764
Drug: Topical steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids, topical antibiotics, and lubricating drops
Study: 10874258
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg) alone
Study: 1587753
Drug: Stereotactic interstitial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic interstitial brachytherapy with iodine-125 implants
Study: 30255418
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg BID
Study: 20721488
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg body weight of oral praziquantel divided in two equal doses with 1 h interval (Group 1)
Study: 20721488
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg body weight of oral praziquantel (Group 2)
Study: 12534505
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type B (3 injections of 250 U each, total 750 U)
Study: 8638792
Drug: Verapamil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 0.1 mg/kg
Study: 8638792
Drug: Verapamil 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 0.05 mg/kg
Study: 8638792
Drug: Diltiazem 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 0.2 mg/kg
Study: 8186137
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg/day)
Study: 8186137
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg/day)
Study: 2526824
Drug: Acitretin 25
Normalized name: acitretin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 25 mg/day
Study: 22816881
Drug: Acitretin 35
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 35 mg/day
Study: 2467488
Drug: Acitretin 45
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 45 mg/day
Study: 2467488
Drug: Acitretin 55
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 55 mg/day
Study: 2467488
Drug: Acitretin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (after discontinuation)
Study: 2467488
Drug: Acitretin (dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (dosages 45 or 55 mg/day)
Study: 19623197
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg daily)
Study: 17244103
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (Duragesic, 25 microg/h)
Study: 15492435
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times a week for 12 weeks
Study: 9561935
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (i.t.)
Study: 10163331
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with antisecretory or cytoprotective drugs
Study: 31802120
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) 3-dose schedule
Study: 31802120
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) 2-dose schedule
Study: 31802120
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) 3-dose schedule
Study: 28333997
Drug: Repetitive practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive practice (same exergame - ski slalom, twice weekly for 20 minutes over 5 weeks)
Study: 18923786
Drug: Sensory-motor-oral stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory-motor-oral stimulation and non-nutritive sucking
Study: 16361296
Drug: Ganirelix (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (0.25 mg/day)
Study: 2401028
Drug: Calan tablet
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calan tablet 5 mg, administered 3 times a day for 6 weeks.
Study: 26992090
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with supplemental insulin
Study: 26992090
Drug: Metformin (Hr1-GTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (Hr1-GTT >212 mg/dL)
Study: 26992090
Drug: Metformin (Wk1-mFG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (Wk1-mFG >95 mg/dL)
Study: 17420344
Drug: Copeptin above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin above the median (approximately 7 pmol/L) in patients with NTproBNP above the median (approximately 900 pmol/L)
Study: 16390748
Drug: LHRH‐A therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH‐A therapy
Study: 12045509
Drug: Combined joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined joint manipulation and myofascial therapy
Study: 10825037
Drug: HA-1A (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (6 mg/kg of body weight iv; maximum, 100 mg)
Study: 8829888
Drug: Oral ebastine
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ebastine
Study: 2704543
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A ointment (all-trans retinoic acid)
Study: 7009819
Drug: Rifampin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (10 mg/kg/dose, 600 mg/dose maximum, twice daily for two days)
Study: 28536029
Drug: CIGB-247 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIGB-247 vaccine with adjuvant VSSP, specific anti-VEGF IgG titer diminished but remained above pre-vaccination levels, gradual shift in anti-VEGF IgG response from IgG1 to IgG4, maintained antibodies able to interfere with VEGF/Receptor interaction, production of IFNγ secretion in CD8+ cells.
Study: 10668836
Drug: Amlodipine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine therapy
Study: 22885164
Drug: Rituximab chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab chemotherapy induction and 2-year rituximab maintenance
Study: 22885164
Drug: Rituximab chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab chemotherapy induction and maintenance
Study: 18335394
Drug: Pharmacological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological intervention with metformin or acarbose
Study: 16277712
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO 40,000 units once per week (group A)
Study: 16277712
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO 40,000 units three times per week (group B)
Study: 16277712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous iron saccharate alone)
Study: 7917794
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) alone
Study: 2288835
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) after pretreatment with oral co-trimoxazole
Study: 6352641
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azlocillin and tobramycin
Study: 22516668
Drug: Untried atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untried atypical antipsychotic (phase 2E)
Study: 19408475
Drug: Mineralized collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralized collagen bone substitute (MCBS) combined with recombinant human platelet-derived growth factor-BB (0.3 mg/mL)
Study: 17761236
Drug: Nutrition computer
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition computer modules (oral rehydration therapy, calcium, and vitamins) on compact disc for study over 6 weeks
Study: 2502417
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg simvastatin
Study: 7848228
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg prostaglandin F2 alpha (PGF2 alpha) applied intracervically
Study: 7848228
Drug: Standard oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard oxytocin intravenous infusion
Study: 6203496
Drug: Electroconvulsive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive treatments (ECTs)
Study: 21177797
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg soy hypocotyl isoflavones
Study: 16187969
Drug: BMT (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT (bismuth biskalcitrate, metronidazole, tetracycline) administered with food
Study: 12792359
Drug: Group drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group drug counseling (GDC)
Study: 10669989
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with triple regimen
Study: 10669989
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with dual therapy
Study: 30316489
Drug: Audio-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-based cognitive behavioral therapy (ACBT)
Study: 25026919
Drug: Black chokeberry
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black chokeberry juice (89 mL per resident daily for 3 months in group B)
Study: 22261573
Drug: HiCarb/LoProt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiCarb/LoProt diet (glucose 10 mg · kg(‐1) · min(‐1)/protein 0.7 g · kg(‐1) · d(‐1))
Study: 22261573
Drug: NormCarb/LoProt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NormCarb/LoProt diet (glucose 7.5 mg · kg(‐1) · min(‐1)/protein 0.3 g · kg(‐1) · d(‐1))
Study: 20039931
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban with enoxaparin
Study: 20039931
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban with unfractionated heparin (UFH)
Study: 27648752
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for SAD
Study: 20395096
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg of vitamin C)
Study: 18555812
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg ethinyl estradiol plus 3 mg drospirenone (Group A)
Study: 12484508
Drug: CCB (amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB (amlodipine 5 mg once daily)
Study: 12484508
Drug: ACE‐I (temocapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐I (temocapril 2 mg once daily)
Study: 12484508
Drug: ARB (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (candesartan 4 mg once daily) added to CCB
Study: 12484508
Drug: ARB (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (candesartan 4 mg once daily) added to ACE‐I
Study: 10717757
Drug: Amodiaquine 30
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine 30 mg/kg
Study: 17488902
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/kg
Study: 7491391
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of Methylphenidate (MPH)
Study: 7491391
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of Methylphenidate (MPH)
Study: 2975095
Drug: Isradipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0.5 mg)
Study: 1834462
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml solvent)
Study: 28327696
Drug: 1.5 mm
Normalized name: blade lancet, safety 1.5 mm X 2 mm MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mm subcrestal implant placement
Study: 28327696
Drug: 0.5 mm
Normalized name: OptiMARK, 0.5 mmol/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mm subcrestal implant placement
Study: 28873376
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg cathine
Study: 28873376
Drug: 53.3 mg
Normalized name: phosphorus 53.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 53.3 mg cathine
Study: 21153030
Drug: Intravenous L:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L: -arginine (10 g in 20 min)
Study: 30076270
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day donepezil
Study: 11139914
Drug: Steroid-eluting coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-eluting coronary venous leads
Study: 26906129
Drug: Involvement in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement in treatment decision making
Study: 8173149
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg qd
Study: 15694088
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 microg)
Study: 12153552
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg day-1
Study: 9649261
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for 9 months
Study: 30355640
Drug: Daily digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily digital air leak measurements
Study: 21067018
Drug: Injection Spectinomycin
Normalized name: spectinomycin Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Spectinomycin 2 gm
Study: 14600930
Drug: Solid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid meal (100 g ground beef labelled with 25 MBq (99m)Tc sulphur colloid)
Study: 14600930
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal (150 ml 10% glucose drink labelled with 8 MBq (67)Ga citrate)
Study: 9342984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only anesthetic drugs
Study: 31736357
Drug: Udenafil 87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 87.5 mg twice daily
Study: 22016911
Drug: Oral‐B Indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Indicator 35 (compact head)
Study: 27283367
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) plus narrow-band UVB phototherapy for 8 weeks
Study: 31856900
Drug: mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mupirocin ointment
Study: 20461001
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (target concentrations: 4-9 ng/ml; infusion rates: 0.17-9 ng x ml x min)
Study: 20461001
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion with low-dose propofol
Study: 20461001
Drug: Simulation study
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulation study at varying remifentanil infusion speeds
Study: 10822283
Drug: Extruded dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extruded dry beans (110 g/day)
Study: 1623914
Drug: Ketoprofen (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (25 mg)
Study: 6991534
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg)